The FDA has recently approved Zepbound (tirzepatide) as a treatment for moderate to severe OSA in adults with obesity marking a new chapter in sleep apnea care that brings hope, especially for patients looking for a less equipment-heavy approach
Abdominal Pain, Unexplained Weight Loss, or Fatigue: Persistent symptoms like nausea, vomiting, abdominal pain, unexplained weight loss, weakness, or fatigue may require medical evaluation while using Januvia and Jardiance together
Fatigue or weakness may be experienced by some patients, particularly during the initial weeks of therapy, and may be related to reduced caloric intake or metabolic adaptation
doi: 10.3390/plants13010093 268 SainiAShamsRDashKKKovcsB
The same firms produce the new weight-loss drugs, developed initially to treat diabetes, and have been accused of having a stranglehold on that market, charging up to 400 times more than needed for products
This peptide has been studied for its influence on cellular growth pathways involved in muscle adaptation rather than just hypertrophy (increasing the size of existing cells)
